Neisseria gonorrhoeae Infections – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Neisseria gonorrhoeae Infections – Drugs In Development, 2024 report and make more profitable business decisions.
Neisseria gonorrhoeae, the bacterium accountable for the sexually transmitted infection (STI) gonorrhea, is a notable public health issue causing substantial global morbidity in both resource-rich and resource-poor nations. The diagnosis and treatment of this infection entail considerable financial expenditures each year. Similar to other sexually transmitted infections (STIs), gonorrhea has a disproportionate impact on young adults. The obligate human pathogen N. gonorrhoeae predominantly presents as urethritis in men and cervicitis in women.
The Neisseria gonorrhoeae Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Neisseria gonorrhoeae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria gonorrhoeae Infections and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Neisseria gonorrhoeae Infections | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 27 molecules, with 24 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Neisseria gonorrhoeae Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Neisseria gonorrhoeae Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Neisseria gonorrhoeae Infections treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AimMax Therapeutics IncBiocidium Biopharmaceuticals Inc
Collaborations Pharmaceuticals Inc
Debiopharm International SA
Defenition Ltd
Evaxion Biotech A/S
Griffith University
GSK plc
Hackensack Meridian Health Inc
LimmaTech Biologics AG
Microbiotix Inc
Nektr Technologies Ltd
Omvax Inc
Opal Biosciences Ltd
Prokaryotics Inc
Recce Pharmaceuticals Ltd
Taisho Pharmaceutical Holdings Co Ltd
TherapyX Inc
University of Massachusetts Worcester Campus
VenatoRx Pharmaceuticals Inc
Yaso Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Neisseria gonorrhoeae Infections reports